(Q40163779)

English

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

José Luis Pérez-Gracia

object named as

José L Pérez-Gracia

5

0 references

Enriqueta Felip

object named as

Enriqueta Felip

4

0 references

1

object named as

Roy S Herbst

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Julian R Molina

7

object named as

Julian Molina

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Paul Baas

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Dong-Wan Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Ji-Youn Han

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Joo-Hang Kim

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Catherine Dubos Arvis

9

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Myung-Ju Ahn

10

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Margarita Majem

11

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Mary J Fidler

12

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gilberto de Castro

13

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Marcelo Garrido

14

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gregory M Lubiniecki

15

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Yue Shentu

16

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Ellie Im

17

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Marisa Dolled-Filhart

18

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Edward B Garon

19

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

18 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

387

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

10027

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1540-1550

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ceritinib in ALK-rearranged non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to TKIs in solid tumours: learning from lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab for the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The PD-1 pathway in tolerance and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The Efficiency of Cox's Likelihood Function for Censored Data

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2815%2901281-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(15)01281-7

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40163779&oldid=1887809390"